SUMMARY: BACKGROUND: Few studies have assessed the quality of medical care in breast cancer patients outside clinical studies and certified centres in German-speaking countries. We used ONkeyLINE, a voluntary tumour registry, to evaluate the rate of adoption into clinical practice of guidelines on the adjuvant use of trastuzumab and to estimate the reliability of ONkeyLINE in assessing quality of care. MATERIAL AND METHODS: Data from ONkeyLINE were analysed to answer questions on the quality of breast cancer care in daily practice in 2007. The influence of age and area (rural/urban) on treatment patterns was also evaluated. RESULTS: Data from approximately 85% of patients diagnosed with breast cancer in Lower Saxony in 2007 were documented in ONkeyLINE. Within 1 year, more than 77% of patients received adjuvant trastuzumab according to the updated guidelines. Variations in chemotherapy and trastuzumab according to age were evident, in part but not fully attributable to comorbidities in the elderly. Access to trastuzumab therapy in rural areas was as high as in urban areas. CONCLUSIONS: Adoption of national guidelines into clinical practice was observed at a reasonable but still unsatisfactory rate in Lower Saxony. Although voluntary, ONkeyLINE covered most breast cancer cases and proved to be a reliable tool for assessing quality of care.
SUMMARY: BACKGROUND: Few studies have assessed the quality of medical care in breast cancerpatients outside clinical studies and certified centres in German-speaking countries. We used ONkeyLINE, a voluntary tumour registry, to evaluate the rate of adoption into clinical practice of guidelines on the adjuvant use of trastuzumab and to estimate the reliability of ONkeyLINE in assessing quality of care. MATERIAL AND METHODS: Data from ONkeyLINE were analysed to answer questions on the quality of breast cancer care in daily practice in 2007. The influence of age and area (rural/urban) on treatment patterns was also evaluated. RESULTS: Data from approximately 85% of patients diagnosed with breast cancer in Lower Saxony in 2007 were documented in ONkeyLINE. Within 1 year, more than 77% of patients received adjuvant trastuzumab according to the updated guidelines. Variations in chemotherapy and trastuzumab according to age were evident, in part but not fully attributable to comorbidities in the elderly. Access to trastuzumab therapy in rural areas was as high as in urban areas. CONCLUSIONS: Adoption of national guidelines into clinical practice was observed at a reasonable but still unsatisfactory rate in Lower Saxony. Although voluntary, ONkeyLINE covered most breast cancer cases and proved to be a reliable tool for assessing quality of care.
Authors: Ute-Susann Albert; Helmut Altland; Volker Duda; Jutta Engel; Max Geraedts; Syvia Heywang-Köbrunner; Dieter Hölzel; Eva Kalbheim; Michael Koller; Klaus König; Rolf Kreienberg; Thorsten Kühn; Annette Lebeau; Irmgard Nass-Griegoleit; Werner Schlake; Rita Schmutzler; Ingrid Schreer; Hilde Schulte; Rüdiger Schulz-Wendtland; Uwe Wagner; Ina Kopp Journal: J Cancer Res Clin Oncol Date: 2008-07-26 Impact factor: 4.553
Authors: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544
Authors: R W Blamey; B Hornmark-Stenstam; G Ball; M Blichert-Toft; L Cataliotti; A Fourquet; J Gee; K Holli; R Jakesz; M Kerin; R Mansel; R Nicholson; T Pienkowski; S Pinder; M Sundquist; M van de Vijver; I Ellis Journal: Eur J Cancer Date: 2010-01 Impact factor: 9.162
Authors: Shanly C Seferina; Dorien J A Lobbezoo; Maaike de Boer; M Wouter Dercksen; Franchette van den Berkmortel; Roel J W van Kampen; Agnès J van de Wouw; Bart de Vries; Manuela A Joore; Petronella G M Peer; Adri C Voogd; Vivianne C G Tjan-Heijnen Journal: Oncologist Date: 2015-06-22
Authors: Ena Niño de Guzmán; Yang Song; Pablo Alonso-Coello; Carlos Canelo-Aybar; Luciana Neamtiu; Elena Parmelli; Javier Pérez-Bracchiglione; Montserrat Rabassa; David Rigau; Zuleika Saz Parkinson; Iván Solà; Adrián Vásquez-Mejía; Ignacio Ricci-Cabello Journal: Breast Cancer Res Treat Date: 2020-05-06 Impact factor: 4.872